Structure via PubChem · Public domain (PubChem)
pirfenidone
Sign in to saveAlso known as AMR-69, AMR 69
Pirfenidone, sold under the brand name Esbriet among others, is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II.
Key facts
- Drug.image
- Pirfenidone2DACS.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 150
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 417788348
- Drug.tradename
- Esbriet, Pirespa, Etuary
- Drug.MedlinePlus
- a615008
- Drug.licence_EU
- yes
- Drug.DailyMedID
- Pirfenidone
- Drug.pregnancy_AU
- B3
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L04
- Drug.ATC_suffix
- AX05
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C12H11NO
- Molecular weight
- 185.22 g/mol
- IUPAC name
- 5-methyl-1-phenylpyridin-2-one
- SMILES
- CC1=CN(C(=O)C=C1)C2=CC=CC=C2
- InChIKey
- ISWRGOKTTBVCFA-UHFFFAOYSA-N
- XLogP
- 1.9
- Polar surface area
- 20.3 Ų
- H-bond donors
- 0
- H-bond acceptors
- 1
- Formal charge
- 0
via PubChem
Research
2,646 papers- Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2017
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.Lancet (London, England) · 2011
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.BMC pulmonary medicine · 2021
- Pirfenidone as a novel cardiac protective treatment.Heart failure reviews · 2022
- Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.European journal of clinical pharmacology · 2024
via PubMed
~13 min read
Encyclopedic overview
22 sectionsContents
- Medical uses
- Adverse effects
- Gastrointestinal
- Skin
- Hepatic dysfunction
- Dizziness and fatigue
- Weight loss
- Interactions
- CYP1A2 inhibitors
- Other CYP inhibitors
- CYP1A2 inducers
- Cigarette smoking
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- History
- Preclinical studies in models of fibrosis
- Clinical trials in idiopathic pulmonary fibrosis
- Regulatory progress
- Research
- See also
- References
Pirfenidone, sold under the brand name Esbriet among others, is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II.
It was first approved in Japan for the treatment of people with idiopathic pulmonary fibrosis after clinical trials in 2008. It was approved for use in the European Union in 2011, in Canada in 2012, and in the United States in October 2014.
Excerpted from Wikipedia’s “pirfenidone” article, available under the CC BY-SA 4.0 licence.